Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) Short Interest Down 18.7% in January

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 945,998 shares, a drop of 18.7% from the January 12th total of 1,163,534 shares. Based on an average daily trading volume, of 801,494 shares, the short-interest ratio is currently 1.2 days. Currently, 10.1% of the company’s stock are sold short.

Ampliphi Biosciences (APHB) remained flat at $$1.22 during midday trading on Friday. 208,137 shares of the company traded hands, compared to its average volume of 980,607. Ampliphi Biosciences has a twelve month low of $0.67 and a twelve month high of $5.80. The company has a market capitalization of $16.39, a price-to-earnings ratio of -0.12 and a beta of 3.20.

Ampliphi Biosciences (NYSEAMERICAN:APHB) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.37. Ampliphi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%.

Separately, HC Wainwright lifted their price objective on shares of Ampliphi Biosciences from $5.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, January 17th.

WARNING: “Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) Short Interest Down 18.7% in January” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/02/16/ampliphi-biosciences-corp-aphb-short-interest-down-18-7-in-january.html.

Ampliphi Biosciences Company Profile

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply